Open access
Open access
Powered by Google Translator Translator

Oncology – Head and Neck

Salivary gland cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

27 Jan, 2023 | 12:16h | UTC

Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up – ESMO Open

 


RCT | Nivolumab plus Ipilimumab vs. EXTREME regimen as first-line treatment for recurrent/metastatic head and neck cancer

19 Jan, 2023 | 13:41h | UTC

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651 – Journal of Clinical Oncology

Commentary: First-Line Nivolumab/Ipilimumab vs EXTREME Regimen in Recurrent or Metastatic Head and Neck Cancer – The ASCO Post

 


NICE Guideline | Thyroid cancer: assessment and management

11 Jan, 2023 | 14:34h | UTC

Thyroid cancer: assessment and management – National Institute for Health and Care Excellence

 


ASCO Guideline | Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers

9 Jan, 2023 | 14:41h | UTC

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline – Journal of Clinical Oncology

News Release: ASCO Publishes New Guideline on Immunotherapy, Biomarker Testing in Advanced Head and Neck Cancer – ASCO Daily News

 


Cohort Study | Lobectomy vs. total thyroidectomy for intermediate-risk papillary thyroid carcinoma with lymph node metastasis.

6 Dec, 2022 | 13:41h | UTC

Comparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis – JAMA Surgery (free for a limited period)

Invited Commentary: Is Lobectomy as Effective as Total Thyroidectomy in Treating Patients With Intermediate-Risk Papillary Thyroid Carcinoma With Lateral Lymph Node Metastasis? – JAMA Surgery (free for a limited period)

 

Commentary on Twitter

 


Case–control study | GLP-1 receptor agonists linked to increased risk of thyroid cancer.

25 Nov, 2022 | 12:42h | UTC

GLP-1 Receptor Agonists and the Risk of Thyroid Cancer – Diabetes Care (link to abstract – $ for full-text)

Commentary: GLP-1 receptor agonists associated with thyroid cancer – ACP Internist

 


RCT | Low-dose immunotherapy (nivolumab) may improve outcomes when added to chemotherapy for head and neck cancer.

7 Nov, 2022 | 12:26h | UTC

Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study – Journal of Clinical Oncology (link to abstract – $ for full-text)

 

Commentary from the author on Twitter

 


2022 ETA Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma.

27 Oct, 2022 | 12:33h | UTC

2022 ETA Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma – European Thyroid Journal

Commentary: New EU Guidelines: Individualize Care for Thyroid Cancer in Kids – Medscape (free registration required)

 


RCT | Adjuvant capecitabine following concurrent CTX-RT in locoregionally advanced nasopharyngeal carcinoma.

17 Oct, 2022 | 12:15h | UTC

Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial – JAMA Oncology

 


4-year follow-up of a RCT | Pembrolizumab with vs. without chemotherapy in recurrent or metastatic head and neck SCC.

14 Oct, 2022 | 14:11h | UTC

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study – Journal of Clinical Oncology

Original Study: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study – The Lancet (link to abstract – $ for full-text)

 


Guideline Summary | Recommendations for care of survivors of head and neck cancer.

7 Oct, 2022 | 14:15h | UTC

Recommendations for Care of Survivors of Head and Neck Cancer – JAMA (free for a limited period)

Original Guideline: Head and neck cancer survivorship consensus statement from the American Head and Neck Society – Laryngoscope Investigative Otolaryngology

Related:

Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline – Journal of Clinical Oncology

American Cancer Society Head and Neck Cancer Survivorship Care Guideline

 


RCT | Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer.

3 Oct, 2022 | 13:42h | UTC

Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA) – Journal of Clinical Oncology

Commentary: Selumetinib Does Not Improve CR Rate in Differentiated Thyroid Cancer – Cancer Therapy Adviser

 

Commentary on Twitter

 


M-A of randomized trials | Prophylactic central neck lymph node dissection in low-risk thyroid carcinoma patients does not decrease the incidence of locoregional recurrence.

21 Sep, 2022 | 13:07h | UTC

Prophylactic Central Neck Lymph Node Dissection in Low-risk Thyroid Carcinoma Patients Does Not Decrease the Incidence of Locoregional Recurrence: A Meta-analysis of Randomized Trials – Annals of Surgery (link to abstract – $ for full-text)

 


Noninferiority RCT | Induction chemotherapy regimen of docetaxel plus cisplatin vs. docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.

6 Sep, 2022 | 14:29h | UTC

Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial – eClinicalMedicine

 


Guideline | Patient preparation and radiation protection guidance for adult patients undergoing radioiodine treatment for thyroid cancer.

1 Sep, 2022 | 11:53h | UTC

Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK – Clinical Oncology

 


RCT | In patients with low-risk nasopharyngeal carcinoma, radiotherapy alone was noninferior to radiotherapy plus concurrent chemoradiotherapy on survival without disease relapse at 3 years.

25 Aug, 2022 | 12:13h | UTC

Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial – JAMA (free for a limited period)

Video Editor’s Note: Radiotherapy With vs Without Chemoradiotherapy in Low-risk Nasopharyngeal Carcinoma – JAMA

 


The contemporary management of cancers of the sinonasal tract in adults.

16 Aug, 2022 | 13:39h | UTC

The contemporary management of cancers of the sinonasal tract in adults – CA: A Cancer Journal for Clinicians

 


Guideline | Pediatric differentiated thyroid carcinoma.

29 Jul, 2022 | 12:31h | UTC

Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline – Endocrine-Related Cancer

 


Phase 2 RCT | Deintensified chemoradiotherapy for pretreatment Epstein-Barr Virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma.

19 Jul, 2022 | 12:58h | UTC

Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentaries:

#VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma – Physician’s Weekly

Intensity-Modulated Radiotherapy Plus 2 Cycles of Concurrent Cisplatin Improved Low-Risk LA-NPC Outcomes – Cancer Network

 

Commentary on Twitter

 


Evaluation of the molecular landscape of pediatric thyroid nodules and use of a multigene genomic classifier in children.

8 Jul, 2022 | 11:20h | UTC

Evaluation of the Molecular Landscape of Pediatric Thyroid Nodules and Use of a Multigene Genomic Classifier in Children – JAMA Oncology

 

Commentaries on Twitter

 


Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials.

23 Jun, 2022 | 09:54h | UTC

Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials – Cancer Treatment and Research Communications

 


Health Technology Assessment: Molecular testing for thyroid nodules of indeterminate cytology.

25 May, 2022 | 10:42h | UTC

Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment – Ontario Health Technology Assessment Series

 


M-A: Complication rates of total thyroidectomy vs. hemithyroidectomy for treatment of papillary thyroid microcarcinoma.

11 May, 2022 | 10:59h | UTC

Complication Rates of Total Thyroidectomy vs Hemithyroidectomy for Treatment of Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis – JAMA Otolaryngology-Head & Neck Surgery (link to abstract – $ for full-text)

 

Commentary on Twitter

 


ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer.

5 May, 2022 | 10:16h | UTC

ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer – Annals of Oncology

 


RCT: Effect of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone on progression-free survival among patients with newly diagnosed metastatic nasopharyngeal carcinoma who had received induction chemotherapy.

27 Apr, 2022 | 07:44h | UTC

Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.